These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22296182)

  • 21. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients.
    Meers S; Vandenberghe P; Boogaerts M; Verhoef G; Delforge M
    Leuk Res; 2008 Jul; 32(7):1026-35. PubMed ID: 18006057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.
    Selleri C; Maciejewski JP; Catalano L; Ricci P; Andretta C; Luciano L; Rotoli B
    Cancer; 2002 Nov; 95(9):1911-22. PubMed ID: 12404285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment.
    Barrett J; Sloand E; Young N
    Haematologica; 2006 May; 91(5):583-4. PubMed ID: 16670061
    [No Abstract]   [Full Text] [Related]  

  • 24. Immune alterations in untreated and treated myelodysplastic syndrome.
    Mewawalla P; Dasanu CA
    Expert Opin Drug Saf; 2011 May; 10(3):351-61. PubMed ID: 21417834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Abnormal polarization of T lymphocyte induces negative hematopoietic regulation in myelodysplastic syndromes].
    Wu LY; Li X; Chang CK; Ying SX; Pu Q
    Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):549-54. PubMed ID: 18078133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating myelodysplastic syndromes.
    Ryan C; McCann S
    IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological abnormalities in myelodysplastic syndromes.
    Hamblin TJ
    Semin Hematol; 1996 Apr; 33(2):150-62. PubMed ID: 8722685
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
    Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
    Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clonal expanded T-cell repertoire in MDS].
    Li YQ; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):793-7. PubMed ID: 20561453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Auto- and alloreactivity of T lymphocytes in myelodysplastic syndrome].
    Cukrová V; Neuwirtová R; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
    Cas Lek Cesk; 2006; 145(8):647-52; discussion 653. PubMed ID: 16995421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging drugs for the treatment of myelodysplastic syndrome.
    Nivatpumin PJ; Gore SD
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):569-90. PubMed ID: 16083330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulation in myelodysplastic syndromes.
    Sekeres MA; List A
    Best Pract Res Clin Haematol; 2006; 19(4):757-67. PubMed ID: 16997181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current therapeutic approaches for patients with myelodysplastic syndromes.
    Greenberg PL
    Br J Haematol; 2010 Jul; 150(2):131-43. PubMed ID: 20507314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
    Warlick ED; Miller JS
    Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset.
    Fozza C; Contini S; Galleu A; Simula MP; Virdis P; Bonfigli S; Longinotti M
    Exp Hematol; 2009 Aug; 37(8):947-55. PubMed ID: 19409953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunological indices in myelodysplastic syndromes].
    Luraschi A; Saglietti G; Fedeli P; Gioria A; Della Vedova A; Ferrari V; Borgotti P
    Minerva Med; 1994 Apr; 85(4):145-53. PubMed ID: 8028741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study.
    Giannouli S; Voulgarelis M; Zintzaras E; Tzioufas AG; Moutsopoulos HM
    Rheumatology (Oxford); 2004 May; 43(5):626-32. PubMed ID: 14983106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapies in myelodysplastic syndrome.
    Melchert M; List A
    Semin Hematol; 2008 Jan; 45(1):31-8. PubMed ID: 18179967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes.
    List AF
    Forum (Genova); 1999; 9(1):35-45. PubMed ID: 10101209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.